FDA gives the OK to Chiesi for treatment of ultra-rare enzyme deficiency disease
The FDA handed down an approval Thursday for Chiesi’s velmanase alfa, an enzyme supplement designed to treat non-central nervous system manifestations of an ultra-rare progressive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
